IMO Team CHM used its IMU know how and was able to apply it to speed up the pipeline progress at CHM. The connections with City of Hope were already established and bonding with Penn was easier to achieve due to their experiences in licencing.
IMU's take off was subdued and delayed due to the market's low opinion, treating IMU just as a wannabe like all the other one trick ponies. But that changed with Her-Vaxx Ph1 / Ph2 trial success and the OV CF 33 related trial IND / ethnical approvals.
Hopper and Co now have their brilliant reputation established and more and more market participants have realised that. From that point CHM should be valued in the 500m-1b range too as it has NK and Brain Cancer CAR-T already in human trials and the CDH 17 CAR-T is about to get into clinical trials soon.
Grab them while cheap.
GLTA
CHM Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
